This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Our primary areas of research are drug discovery and development. Research currently includes the design and synthesis of novel topoisomerase I and II poisons as antineoplastic agents. Several potent topoisomerase poisons have been identified and studies are in progress to identify those with the greater potential to serve as clinical candidates. Research has also been undertaken on the synthesis of analogs of the cancer chemotherapeutic agent, hexamethylmelamine or Altretamine, as well as prodrugs of its suspect active metabolite. Mechanisms of carcinogenesis are being investigated by examining the potential role of metabolites of polycyclic aromatic compounds in cancer initiation and tumor growth.
Showing the most recent 10 out of 696 publications